Gut microbiota as a promising therapeutic target for age-related sarcopenia

Ting Zhang; Jin-Ke Cheng; Yao-Min Hu

doi:10.1016/j.arr.2022.101739

Gut microbiota as a promising therapeutic target for age-related sarcopenia

Ageing Res Rev. 2022 Nov:81:101739. doi: 10.1016/j.arr.2022.101739. Epub 2022 Sep 28.

Authors

Ting Zhang¹, Jin-Ke Cheng², Yao-Min Hu³

Affiliations

¹ Department of Geriatrics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China.
² State Key Laboratory of Oncogenes and Related Genes, Renji Hospital Affiliated, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Department of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
³ Department of Geriatrics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China. Electronic address: amin99@163.com.

PMID: 36182084
DOI: 10.1016/j.arr.2022.101739

Abstract

Sarcopenia is characterized by a progressive loss of skeletal muscle mass and function with aging. Recently, sarcopenia has been shown to be closely related with gut microbiota. Strategies such as probiotics and fecal microbiota transplantation have shown potential to ameliorate the muscle loss. This review will focus on the age-related sarcopenia, in particular on the relationship between gut microbiota and age-related sarcopenia, how gut microbiota is engaged in sarcopenia, and the potential role of gut microbiota in the treatment of age-related sarcopenia.

Keywords: Aging; Gut microbiota; Microbiota; Probiotics; Sarcopenia; Skeletal muscle.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Aging / physiology
Fecal Microbiota Transplantation
Gastrointestinal Microbiome* / physiology
Humans
Muscle, Skeletal / physiology
Sarcopenia*